AbbVie (ABBV)

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.

His AbbVie purchase was a big move into a high-yielding dividend stock.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Both of these healthcare leaders are Dividend Kings.

Income generation is more about finding consistency than finding an ultra-high yield.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.

They have businesses built to handle the toughest environments.

AbbVie has another blockbuster business emerging.

The drugmaker should significantly mitigate its most important risk as it develops new products.

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per...

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Both of these stocks pay more than double the S&P 500 average of 1.1%.

The pharmaceutical company hopes that another big-time acquisition will pay off.

The stock is up just 8% this year and could prove to be an undervalued buy.

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

This risk is weighing on the stock.

AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales gr...